The trial tested ION269, an experimental drug from Ionis Pharmaceuticals, Inc. delivered into the spinal fluid. The goal was to see if a single dose could be given safely to adults with Down syndrome ...

Besides Wall Street's top-and-bottom-line estimates for Ionis Pharmaceuticals (IONS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared ...

FDA approval puts Wainua at the center of the Ionis story Ionis Pharmaceuticals (IONS) is in the spotlight after securing FDA approval for Wainua, its first fully owned commercial therapy. This ...

Ionis Pharmaceuticals, Inc. today announced that management will participate in fireside chats at the following investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Virtual ...

Catalyst Pharmaceutical (CPRX) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2025. This widely-known consensus ...

Long an R&D company that partnered off assets, RNAi biotech Ionis Pharmaceuticals shifted in 2025 to bring two medicines to market alone. Analysts are already impressed—and there’s more to come in ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced a change in the start time for its fourth quarter and full year ...

Spyre stands out for its deep immunology pipeline, strong cash runway into 2H28, and emerging leadership in TL1A-targeted therapies. With a pro-forma cash position of $783M, SYRE is well-capitalized ...

Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its ...

According to TipRanks.com, Phipps is a 4-star analyst with an average return of 6.6% and a 49.0% success rate. Phipps covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma ...

OliX Pharmaceuticals is joining hands with the French bio corporations "VECT-Horus" to verify delivery technology for short interfering RNA (siRNA) therapies for central nervous system (CNS) diseases.

Ionis Pharmaceuticals Inc. research and ratings by Barron's. View IONS revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.